EGFR and non-small cell lung carcinoma: To investigate the changes in the TME occurring after EGFR inhibition via TKI therapy, we treated autochthonous EGFRL858R-driven NSCLC mice with vehicle, aPD-1, erlotinib, or aPD-1 + erlotinib to assess and compare the effects of both immunotherapy and targeted therapy approaches (Figure 1A).